Swiss contract drug manufacturer Lonza confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business.
Oct 23 (Reuters) – Swiss contract drug manufacturer Lonza (LONN.S), opens new tab confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business.
The Basel-ba… [2229 chars]
Source: Reuters | Published: 2025-10-23T06:36:03Z
Credit: Reuters
